Search

Your search keyword '"Hariklia Kranidioti"' showing total 39 results

Search Constraints

Start Over You searched for: Author "Hariklia Kranidioti" Remove constraint Author: "Hariklia Kranidioti" Database OpenAIRE Remove constraint Database: OpenAIRE
39 results on '"Hariklia Kranidioti"'

Search Results

1. Do the Kinetics of Antibody Responses Predict Clinical Outcome in Hospitalized Patients With Moderate-to-Severe COVID-19?

2. Direct-acting antiviral treatment for chronic hepatitis C in people who use drugs in a real-world setting

Catalog

Books, media, physical & digital resources

3. Endotoxin Translocation and Gut Barrier Dysfunction Are Related to Variceal Bleeding in Patients With Liver Cirrhosis

4. Two-year safety and efficacy of tenofovir alafenamide in chronic hepatitis B: a HEllenic multicenter ReAl-life CLInical Study (HERACLIS-TAF)

5. Real-Life Effectiveness and Safety of Baricitinib as Adjunctive to Standard-of-Care Treatment in Hospitalized Patients With Severe Coronavirus Disease 2019

6. A typical autoimmune hepatitis (AIH) case following Covid‐19 mRNA vaccination. More than a coincidence?

7. Current Management of HCV Genotype 3 Infection

8. Long-term clinical outcome of HBeAg-negative chronic hepatitis B patients who discontinued nucleos(t)ide analogues

9. Monitoring and comorbidities in patients with chronic hepatitis B currently treated with nucleos(t)ide analogs

10. Hepatitis B s antigen kinetics during treatment with nucleos(t)ides analogues in patients with hepatitis B e antigen-negative chronic hepatitis B

11. Real-world experience from tenofovir alafenamide use in chronic hepatitis B: an Hellenic multicenter real-life clinical study (HERACLIS-TAF)

12. Sa325 THE EFFECT OF DIRECT ACTING ANTIVIRAL (DAA) THERAPY ON THE QUALITY OF LIFE (QOL) OF PATIENTS WITH CHRONIC HEPATITIS C (CHC) WHO ATTEND OPIOID SUBSTITUTION (OST) PROGRAMS IN GREECE

13. 441 HEPATITIS C VIRUS (HCV) MICRO-ELIMINATION PROJECT AT OPIOID SUBSTITUTION THERAPY (OST) PROGRAMS IN GREECE

14. Sa314 PREDICTORS OF LIVER STIFFNESS CHANGES IN CHRONIC HEPATITIS B (CHB) PATIENTS UNDER LONG-TERM THERAPY WITH TENOFOVIR DISOPROXIL FUMARATE (TDF)

15. Sa323 HCV REINFECTION AFTER SUCCESSFUL TREATMENT WITH DIRECT-ACTING ANTIVIRAL THERAPY (DAA) IN PEOPLE WHO INJECT DRUGS (PWID)

16. Evaluation of liver fibrosis by transient elastography (FibroScan®) in rheumatic patients during methotrexate treatment

17. Sa1521 LONG-TERM OUTCOME IN NON-CIRRHOTIC PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B (CHB) WHO STOPPED ENTECAVIR (ETV) OR TENOFOVIR (TDF) THERAPY. FINAL RESULTS OF A MULTICENTER PROSPECTIVE STUDY

18. Sa1524 FACTORS THAT MAY AFFECT THE CHANGES OF LIVER STIFFNESS MEASUREMENTS ASSESSED BY TRANSIENT ELASTOGRAPHY (TE) IN PATIENTS WITH CHRONIC HEPATITIS B (CHB) ON LONG-TERM THERAPY WITH TENOFOVIR DISOPROXIL FUMARATE (TDF)

19. Hepatitis B and C coinfection in a real-life setting: viral interactions and treatment issues

20. SAT-004-Bacterial translocation in patients with liver cirrhosis and variceal bleeding

21. ' Bacterial infections in patients with liver cirrhosis: clinical characteristics and the role of C-reactive protein'

22. Scale up of hepatitis C virus treatment in the era of all-oral direct-acting antivirals: a 9-year Greek cohort study

23. Tu1478 – Rest-B Study: Liver Fibrosis Regression Assessed by Transient Elastography (TE) in Patients with Chronic Hepatitis B (CHB) on Long Term Maintenance Therapy with Tenofovir Disoproxil Fumarate (TDF)

24. Tu1506 – Adherence to Follow-Up of People Who Inject Drugs (PWID) After the Successful Treatment of Chronic Hepatitis C with Direct-Acting Antivirals (DAA)

25. KIR2DS2 recognizes conserved peptides derived from viral helicases in the context of HLA-C

26. Elastography for Hepatic Fibrosis Severity in Chronic Hepatitis B or C

27. An early circulating factor in severe sepsis modulates apoptosis of monocytes and lymphocytes

28. Comorbidities in chronic hepatitis B patients currently treated with nucleos(t)ide analogues

29. OLEUROPEIN

30. Η σημασία της αγγειοποιητίνης-2 στο σηπτικό σύνδρομο

31. Sarcoid-like granulomatosis in patients treated with anti-TNFα factors. A case report and review of the literature

32. Angiopoietin-2 is increased in septic shock: evidence for the existence of a circulating factor stimulating its release from human monocytes

33. Pharmacokinetics of moxifloxacin in non-inflamed cerebrospinal fluid of humans: implication for a bactericidal effect

35. 481 THE USEFULNESS OF TRANSIENT ELASTOGRAPHY (TE) IN THE ACCURATE ASSESSMENT OF PATIENTS WITH HBEAG-NEGATIVE CHRONIC HBV INFECTION (CHBVE-)

37. Su1018 Discontinuation of Long-Term Nucleos(T)Ide Analogue(S) [Na(S)] Therapy in HBeAg-Negative Chronic Hepatitis B (Chbe-) Patients Without Cirrhosis: A Prospective Study

38. 1354 HEPATITIS C VIRUS REINFECTION FOLLOWING SUSTAINED VIROLOGICAL RESPONSE IN INTRAVENOUS DRUG USERS

39. Early alterations of the innate and adaptive immune statuses in sepsis according to the type of underlying infection